I Read Between the Lines
After listening to today's presentation for a second time, but now in the comfort of my home and with no interruptions, I was able to read between the lines and realized that Harvey was telling us something that we all wanted to know.
Allow me to first give you statements from the presentation, that easily led me to the realization as to what Harvey was telling us:
1- In the next few months we will be setting up a foreign office in Switzerland.
2- We believe that the 113 Phase 1/2 "will move forward quickly'
3- "Ponatinib and 113 form the foundation for the future of the company".
4- There will be "multiple near term value drivers for both Ponatinib and 113. I won't go into details"
I am sure that many of you by now also realize that Harvey was telling us that 113 is enrolling quickly and showing efficacy and that he was confident of it's eventual approval. "I won't go into details", certainly tells us that he does have details. Having dosed the first patient on September 21, 2011, I believe that by now they have some feedback on efficacy, even though it may be very early data.
To me, this presentation sounded noticeably different than his usual presenation in that it seemed he was talking to the Ariad shareholders, not the JP Morgan clients. A few examples as to whay I got this impression are as follows:
1- After the usual opening remarks and the obligatory forward looking statements disclosure, his opening remark was, "No more partnerships". I can't think of any other group, except we shareholders, that that statement was meant for, or would have as much meaning and importance.
2- I don't recall Harvey ever being so transparent on discussions about Ariad's strategy, at any prior conference, except annual meetings and quarterly shareholder conferences. He sure sounded like he was talking to us shareholders.
3- Substituting his usual professor like discussion of the drugs and diseases we ae targeting, with a fairly in depth (for Harvey)discussion of the market for Ponatinib.
As usual JMHO,
Barry
AI
